Cited by 131Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement DisordersNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.

Serotonin–dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias

CARTA, M, CARLSSON, T, MUNOZ, A, KIRIK, D, BJORKLUND, A·2008·Progress in brain research

DOI 10.1016/s0079-6123(08)00922-9

Open this paper in CoChat — free account

Abstract

Appearance of dyskinesia is a common problem of long-term Levodopa (L-DOPA) treatment in Parkinson's disease (PD) patients and represents a major limitation for the pharmacological management of the motor symptoms in the advanced stages of disease. An increasing body of evidence points to dopamine released as a false neurotransmitter from the striatal serotonin terminals as the main pre-synaptic determinant of L-DOPA-induced dyskinesia. Here we review the animal experimental and human clinical data in support of this view, which point to the serotonin system as a promising target for anti-dyskinetic therapy in PD patients under L-DOPA medication.

Integrity signals

Registry

Crossref · 10.1016/s0079-6123(08)00922-9

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Parkinson disease
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals
Steinbusch, H. W. M. (1981) · Neuroscience · doi:10.1016/0306-4522(81)90146-9 · Cited by 2,415
Molecular, pharmacological and functional diversity of 5-HT receptors
Hoyer, D., Hannon, J. P., & Martin, G. R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00746-8 · Cited by 1,898
Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,456
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
Description of Parkinson's Disease as a Clinical Syndrome
Fahn, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07458.x · Cited by 979
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey
Langston, J. W., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922
Dopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865
Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists
Sprouse, J. S., & Aghajanian, G. K. (1987) · Synapse · doi:10.1002/syn.890010103 · Cited by 848
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N., & Cenci, M. A. (2002) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01843.x · Cited by 664
L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA
Cenci, M. A., Lee, C. S., & Björklund, A. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.t01-1-00285.x · Cited by 649
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
Carta, M., Carlsson, T., Kirik, D., & Björklund, A. (2007) · Brain · doi:10.1093/brain/awm082 · Cited by 637
E PIDEMIOLOGY OF N EURODEGENERATION
Mayeux, R. P. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.043002.094919 · Cited by 531
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P., Feyder, M. T., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 492
Levodopa motor complications in Parkinson's disease
Obeso, J. A., Olanow, C. W., & Nutt, J. G. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00031-8 · Cited by 478
Dopamine and serotonin: influences on male sexual behavior
Hull, E. M., Muschamp, J. W., & Sato, S. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.08.018 · Cited by 465
Critical Involvement of cAMP/DARPP-32 and Extracellular Signal-Regulated Protein Kinase Signaling in L-DOPA-Induced Dyskinesia
Santini, E., Valjent, E., Usiello, A., Carta, M., Borgkvist, A., Girault, J., Hervé, D., Greengard, P., & Fisone, G. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0852-07.2007 · Cited by 447
Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule
Yabut, J. M., Crane, J. D., Green, A. E., Keating, D. J., Khan, W. I., & Steinberg, G. R. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00283 · Cited by 436
1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra
Langston, J. W., Irwin, I., Langston, E. B., & Forno, L. S. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90293-3 · Cited by 435
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias
de la Fuente‐Fernández, R. (2004) · Brain · doi:10.1093/brain/awh290 · Cited by 404
Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia
Aubert, I., Guigoni, C., Håkansson, K., Li, Q., Doveró, S., Barthe, N., Bioulac, B. H., Gross, C. E., Fisone, G., Bloch, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20296 · Cited by 400
Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain — a combined in situ hybridisation/in vitro receptor autoradiographic study
Chalmers, D. T., & Watson, S. J. (1991) · Brain Research · doi:10.1016/0006-8993(91)90748-k · Cited by 388
Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity
Calabresi, P., Gubellini, P., Centonze, D., Picconi, B., Bernardi, G., Chergui, K., Svenningsson, P., Fienberg, A. A., & Greengard, P. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-22-08443.2000 · Cited by 379
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
Kish, S. J., Tong, J., Hornykiewicz, O., Rajput, A. H., Chang, L.-J., Guttman, M., & Furukawa, Y. (2007) · Brain · doi:10.1093/brain/awm239 · Cited by 376
Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane
Dunah, A. W., & Standaert, D. G. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-15-05546.2001 · Cited by 374
DAncing past the DAT at a DA synapse
Cragg, S. J., & Rice, M. E. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.03.011 · Cited by 373
Striatal fosB Expression Is Causally Linked with l-DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin mRNA in a Rat Model of Parkinson's Disease
Andersson, M., Hilbertson, A., & Cenci, M. A. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0259 · Cited by 350
Serotonin and the sleep/wake cycle: special emphasis on microdialysis studies
Portas, C. M., Bjorvatn, B., & Ursin, R. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00097-5 · Cited by 339
L-Dopa: Effect on Concentrations of Dopamine, Norepinephrine, and Serotonin in Brains of Mice
Everett, G. M., & Borcherding, J. W. (1970) · Science · doi:10.1126/science.168.3933.849 · Cited by 333
L-Dopa-Induced Release of Cerebral Monoamines
Ng, K. Y., Chase, T. N., Colburn, R. W., & Kopin, I. J. (1970) · Science · doi:10.1126/science.170.3953.76 · Cited by 331
Serotonin and motor activity
Jacobs, B. L., & Fornal, C. A. (1997) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(97)80141-9 · Cited by 311
Serotonin in Parkinson's disease
Politis, M., & Niccolini, F. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.037 · Cited by 307
Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats
Tanaka, H., Kannari, K., Maeda, T., Tomiyama, M., Suda, T., & Matsunaga, M. (1999) · Neuroreport · doi:10.1097/00001756-199902250-00034 · Cited by 302
Dopamine Synthesis, Uptake, Metabolism, and Receptors: Relevance to Gene Therapy of Parkinson's Disease
Elsworth, J. D., & Roth, R. H. (1997) · Experimental Neurology · doi:10.1006/exnr.1996.6379 · Cited by 282
Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s Disease
Langston, J. W., & Ballard, P. (1984) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046333 · Cited by 281
Real‐time decoding of dopamine concentration changes in the caudate–putamen during tonic and phasic firing
Venton, B. J., Zhang, H., Garris, P. A., Phillips, P. E. M., Sulzer, D., & Wightman, R. M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02109.x · Cited by 281
A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia
Gardoni, F., Picconi, B., Ghiglieri, V., Polli, F., Bagetta, V., Bernardi, G., Cattabeni, F., Luca, M. D., & Calabresi, P. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.5326-05.2006 · Cited by 280
Molecular and anatomical organization of the dorsal raphe nucleus
Huang, K. W., Ochandarena, N. E., Philson, A. C., Hyun, M., Birnbaum, J. E., Cicconet, M., & Sabatini, B. L. (2019) · eLife · doi:10.7554/elife.46464 · Cited by 267
Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia
Ottosson, D. R., Parent, M., O’Sullivan, S. S., Doveró, S., Lees, A. J., Bézard, E., Descarries, L., & Cenci, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.22097 · Cited by 265
Cholinergic Dysfunction in Parkinson’s Disease
Müller, M. L. T. M., & Bohnen, N. I. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0377-9 · Cited by 264
l‐DOPA‐induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia
Lindgren, H. S., Andersson, D. R., Lagerkvist, S., Nissbrandt, H., & Cenci, M. A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06556.x · Cited by 264
Alterations in Subunit Expression, Composition, and Phosphorylation of Striatal N-Methyl-d-Aspartate Glutamate Receptors in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease
Dunah, A. W., Wang, Y., Yasuda, R. P., Kameyama, K., Huganir, R. L., Wolfe, B. B., & Standaert, D. G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23206-5 · Cited by 262
Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial
Goetz, C. G., Damier, P., Hicking, C., LASKA, E. M., Müller, T. H., Olanow, C. W., Rascol, O., & Russ, H. (2006) · Movement Disorders · doi:10.1002/mds.21226 · Cited by 260
Serotonin in Pain and Analgesia: Actions in the Periphery
Sommer, C. (2004) · Molecular Neurobiology · doi:10.1385/mn:30:2:117 · Cited by 256
Reward and aversion
Hu, H. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014106 · Cited by 253
MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects.
Langston, J. W., Langston, E. B., & Irwin, I. (1984) · PubMed · Cited by 252
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients
Politis, M., Wu, K., Loane, C., Brooks, D. J., Kiferle, L., Turkheimer, F., Bain, P. G., Molloy, S., & Piccini, P. P. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71640 · Cited by 245
Toward a unified theory of serotonin dysregulation in eating and related disorders
Brewerton, T. D. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(95)00001-5 · Cited by 245
Differential effects of 5-hydroxytryptamine1A selective drugs on the 5-HT behavioral syndrome
Smith, L. M., & Peroutka, S. J. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90477-6 · Cited by 245
Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study
Politis, M., Wu, K., Loane, C., Kiferle, L., Molloy, S., Brooks, D. J., & Piccini, P. P. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.028 · Cited by 242
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
Bibbiani, F., Oh, J. D., & Chase, T. N. (2001) · Neurology · doi:10.1212/wnl.57.10.1829 · Cited by 241
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
Muñoz, A., Li, Q., Gardoni, F., Marcello, E. E., Qin, C., Carlsson, T., Kirik, D., Luca, M. D., Björklund, A., Bézard, E., et al. (2008) · Brain · doi:10.1093/brain/awn235 · Cited by 241
Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey
Lavoie, B. A., & Parent, A. (1990) · The Journal of Comparative Neurology · doi:10.1002/cne.902990102 · Cited by 239
Maladaptive striatal plasticity in l-DOPA-induced dyskinesia
Cenci, M. A., & Konradi, C. L. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)83011-0 · Cited by 229
The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors.
Peter, D., Jimenez, J., Liu, Y., Kim, M., & Edwards, R. H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37272-1 · Cited by 227
Cellular and subcellular localization of 5-hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies
Sari, Y., Miquel, M., Brisorgueil, M., Ruiz, G., Doucet, E., Hamon, M., & Vergé, D. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00256-5 · Cited by 222
Role of the medial prefrontal cortex in 5‐HT1A receptor‐induced inhibition of 5‐HT neuronal activity in the rat
Hajós, M., Hajós‐Korcsok, É., & Sharp, T. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702510 · Cited by 210
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia
Lundblad, M., Usiello, A., Carta, M., Håkansson, K., Fisone, G., & Cenci, M. A. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.02.002 · Cited by 210
Continuous dopamine-receptor stimulation in early Parkinson's disease
Olanow, C. W., Schapira, A. H. V., & Rascol, O. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00030-6 · Cited by 208
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
Hallett, P. J., Dunah, A. W., Ravenscroft, P., Zhou, S., Bezard, E., Crossman, A. R., Brotchie, J. M., & Standaert, D. G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.11.008 · Cited by 192
Serotonin Neuron Transplants Exacerbate l-DOPA- Induced Dyskinesias in a Rat Model of Parkinson's Disease
Carlsson, T., Carta, M., Winkler, C., Björklund, A., & Kirik, D. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2079-07.2007 · Cited by 191
Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.01.012 · Cited by 187
Serotonin neurons, neuroplasticity, and homeostasis of neural tissue
Azmitia, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00022-6 · Cited by 184
l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study
Arai, R., Karasawa, N., Geffard, M., & Nagatsu, I. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11817-g · Cited by 184
Levodopa therapy
Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.50.5_suppl_5.s17 · Cited by 180
Dopamine D1-Dependent Trafficking of Striatal N-Methyl-d-aspartate Glutamate Receptors Requires Fyn Protein Tyrosine Kinase but Not DARPP-32
Dunah, A. W., Sirianni, A. C., Fienberg, A. A., Bastia, E., Schwarzschild, M. A., & Standaert, D. G. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.1.121 · Cited by 175
Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study)
Olanow, C. W., Damier, P., Goetz, C. G., Mueller, T. J., Nutt, J. G., Rascol, O., Serbanescu, A., Deckers, F., & Russ, H. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200403000-00003 · Cited by 175
Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies
DIMATTEO, V., Giovanni, G. D., Pierucci, M., & Esposito, E. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00902-3 · Cited by 173
Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease
Pisani, A., Centonze, D., Bernardi, G., & Calabresi, P. (2005) · Movement Disorders · doi:10.1002/mds.20394 · Cited by 171
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
Svenningsson, P., Rosenblad, C., Arvidsson, K. A. E., Wictorin, K., Keywood, C., Shankar, B., Lowe, D. A., Björklund, A., & Widner, H. (2015) · Brain · doi:10.1093/brain/awu409 · Cited by 162
Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease
Bara‐Jimenez, W., Bibbiani, F., Morris, M. J., Dimitrova, T. D., Sherzai, A., Mouradian, M. M., & Chase, T. N. (2005) · Movement Disorders · doi:10.1002/mds.20370 · Cited by 160
Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenousl-DOPA in the rat, with reference to the involvement of aromaticl-amino acid decar☐ylase
Arai, R., Karasawa, N., Geffard, M., Nagatsu, T., & Nagatsu, I. (1994) · Brain Research · doi:10.1016/0006-8993(94)91511-3 · Cited by 156
Chronic l ‐DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease
Robelet, S., Melon, C., Guillet, B. A., Salin, P., & Goff, L. K. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03591.x · Cited by 151
Autonomic involvement in Parkinson's disease: Pathology, pathophysiology, clinical features and possible peripheral biomarkers
Cersosimo, M. G., & Benarroch, E. E. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.09.030 · Cited by 151
Amantadine for dyskinesia in Parkinson's disease
Crosby, N. J., Deane, K. H., & Clarke, C. E. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003467 · Cited by 146
Progression of monoaminergic dysfunction in parkinson's disease: a longitudinal 18f-dopa pet study
Pavese, N., Rivero-Bosch, M., Lewis, S. J., Whone, A. L., & Brooks, D. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.012 · Cited by 145
The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy
Jaunarajs, K. L. E., Gupta, V., Alam, S., Park, J. Y., & Bishop, C. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.05.002 · Cited by 144
5‐hydroxytryptamine (5‐HT, serotonin) and Parkinson's disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy
Nicholson, S. L., & Brotchie, J. M. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.9.s3.1.x · Cited by 142
Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys
Tahar, A. H., Grégoire, L., Dare, A., Bélanger, N., Meltzer, L. T., & Bédard, P. J. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.10.007 · Cited by 141
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa‐induced dyskinesia
Bézard, E., Tronci, E., Pioli, E. Y., Li, Q., Porras, G., Björklund, A., & Carta, M. (2013) · Movement Disorders · doi:10.1002/mds.25366 · Cited by 136
Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates
Guigoni, C., Doudnikoff, É., Li, Q., Bloch, B., & Bézard, E. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.02.001 · Cited by 136
Activation of 5‐HT1A but not 5‐HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered l ‐DOPA in the striatum with nigrostriatal denervation
Kannari, K., Yamato, H., Shen, H., Tomiyama, M., Suda, T., & Matsunaga, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00184.x · Cited by 133
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD
Bibbiani, F., Oh, J. D., Kielaitė, A., Collins, M. A., Smith, C., & Chase, T. N. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.08.017 · Cited by 130
Potential mechanisms underlying anxiety and depression in Parkinson's disease: Consequences of l-DOPA treatment
Jaunarajs, K. L. E., Angoa‐Pérez, M., Kuhn, D. M., & Bishop, C. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.007 · Cited by 129
Persistent changes in striatal gene expression induced by long‐term l ‐DOPA treatment in a rat model of Parkinson's disease
Westin, J. E., Andersson, M., Lundblad, M., & Cenci, M. A. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01743.x · Cited by 129
Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA
Maeda, T., Nagata, K., Yoshida, Y., & Kannari, K. (2005) · Brain Research · doi:10.1016/j.brainres.2005.04.019 · Cited by 126
The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex
Ceci, A., Baschirotto, A., & Borsini, F. (1994) · Neuropharmacology · doi:10.1016/0028-3908(94)90177-5 · Cited by 126
The role of the dorsal raphe nucleus in the development, expression, and treatment of L ‐dopa‐induced dyskinesia in hemiparkinsonian rats
Jaunarajs, K. L. E., Dupre, K. B., Barnum, C. J., Dickinson, S. O., Park, J. Y., & Bishop, C. (2009) · Synapse · doi:10.1002/syn.20630 · Cited by 124
The role of 5‐HT1B receptors in the regulation of serotonin cell firing and release in the rat brain
Adell, A., Celada, P., & Artigas, F. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00550.x · Cited by 123
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation
Picconi, B., Paillé, V., Ghiglieri, V., Bagetta, V., Barone, I., Lindgren, H. S., Bernardi, G., Cenci, M. A., & Calabresi, P. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.10.001 · Cited by 122
Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex
Casanovas, J. M., Hervás, I., & Artigas, F. (1999) · Neuroreport · doi:10.1097/00001756-199905140-00010 · Cited by 118
In 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates, the Selective 5-Hydroxytryptamine 1a Agonist (R)-(+)-8-OHDPAT Inhibits Levodopa-Induced Dyskinesia but Only with\ Increased Motor Disability
Iravani, M., Tayarani-Binazir, K. A., Chu, W. B., Jackson, M., & Jenner, P. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110429 · Cited by 115
Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic model
de la Fuente‐Fernández, R., Schulzer, M., Mak, E., Calne, D. B., & Stoessl, A. J. (2004) · Brain · doi:10.1093/brain/awh102 · Cited by 112
Aromaticl-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenousl-DOPA to dopamine
Mura, A., Jackson, D., Manley, M. S., Young, S. J., & Groves, P. M. (1995) · Brain Research · doi:10.1016/0006-8993(95)01104-8 · Cited by 112
PET demonstrates reduced dopamine transporter expression in PD with dyskinesias
Troiano, A. R., de la Fuente‐Fernández, R., Sossi, V., Schulzer, M., Mak, E., Ruth, T. J., & Stoessl, A. J. (2008) · Neurology · doi:10.1212/01.wnl.0000338631.73211.56 · Cited by 111
Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
Olanow, C. W., & Obeso, J. A. (2000) · PubMed · Cited by 107
Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.007 · Cited by 102
Regulation of Extracellular Concentrations of 5-Hydroxytryptamine (5-HT) in Mouse Striatum by 5-HT1A and 5-HT1B Receptors
Knobelman, D. A., Kung, H. F., & Lucki, I. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35396-0 · Cited by 99
Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease
Hong, J. Y., Oh, J. S., Lee, I., Sunwoo, M. K., Ham, J. H., Lee, J. E., Sohn, Y. H., Kim, J. S., & Lee, P. H. (2014) · Neurology · doi:10.1212/wnl.0000000000000385 · Cited by 96
The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism
Goodwin, G. M., Souza, R. J. D., Wood, A. J., & Green, A. R. (1986) · Psychopharmacology · doi:10.1007/bf00174066 · Cited by 96
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model
Muñoz, A., Carlsson, T., Tronci, E., Kirik, D., Björklund, A., & Carta, M. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.033 · Cited by 94
Neuropsychologic assessment of patients for movement disorder surgery
Saint‐Cyr, J. A., & Tr�panier, L. L. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5 · Cited by 92
Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum
Lopez, A., Muñoz, A., Guerra, M. J., & Labandeira-García, J. L. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00588-1 · Cited by 91
Loss of Synaptic D1 Dopamine/N-Methyl-d-aspartate Glutamate Receptor Complexes in l-DOPA-Induced Dyskinesia in the Rat
Fiorentini, C., Rizzetti, M. C., Busi, C., Bontempi, S., Collo, G., Spano, P., & Missale, C. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016667 · Cited by 88
Reserpine Pretreatment Prevents Increases in Extracellular Striatal Dopamine Following L‐DOPA Administration in Rats with Nigrostriatal Denervation
Kannari, K., Tanaka, H., Maeda, T., Tomiyama, M., Suda, T., & Matsunaga, M. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0740263.x · Cited by 85
The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice
Yamada, J., Sugimoto, Y., & Horisaka, K. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90205-1 · Cited by 84
Involvement of Sensorimotor, Limbic, and Associative Basal Ganglia Domains in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia
Guigoni, C., Li, Q., Aubert, I., Doveró, S., Bioulac, B. H., Bloch, B., Crossman, A. R., Gross, C. E., & Bézard, E. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.5059-04.2005 · Cited by 84
NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat
Iderberg, H., McCreary, A. C., Varney, M. A., Kleven, M. S., Koek, W., Bardin, L., Depoortère, R., Cenci, M. A., & Newman‐Tancredi, A. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.05.021 · Cited by 80
Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study
Arai, R., Karasawa, N., & Nagatsu, I. (1996) · Brain Research · doi:10.1016/0006-8993(95)01281-8 · Cited by 80
Aromatic L‐amino acid decarboxylase in rat corpus striatum
Melamed, E., Hefti, F. F., Pettibone, D. J., Liebman, J., & Wurtman, R. J. (1981) · Neurology · doi:10.1212/wnl.31.6.651 · Cited by 80
Serotonin-to-dopamine transporter ratios in Parkinson disease
Roussakis, A., Politis, M., Towey, D., & Piccini, P. P. (2016) · Neurology · doi:10.1212/wnl.0000000000002494 · Cited by 79
Serotonin transporter inhibition attenuates l ‐DOPA‐induced dyskinesia without compromising l ‐DOPA efficacy in hemi‐parkinsonian rats
Bishop, C., George, J. A., Buchta, W. C., Goldenberg, A. A., Mohamed, M., Dickinson, S. O., Eissa, S., & Jaunarajs, K. L. E. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08202.x · Cited by 75
Localization and functional significance of striatal neurons immunoreactive to aromatic l-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models
López-Real, A. M., Rodríguez‐Pallares, J., Guerra, M. J., & Labandeira-García, J. L. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02291-1 · Cited by 75
The 5-HT1A receptor and behavioral stimulation in the rat: effects of 8-OHDPAT on spontaneous and cocaine-induced behavior
Carey, R. J., DePalma, G., Damianopoulos, E. N., M�ller, C., & Huston, J. P. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1917-4 · Cited by 74
Effects of sarizotan on the corticostriatal glutamate pathways
Antonelli, T., Fuxé, K., Tomasini, M. C., Bartoszyk, G. D., Seyfried, C. A., Tanganelli, S., & Ferraro, L. (2005) · Synapse · doi:10.1002/syn.20195 · Cited by 74
Do serotonin1–7 receptors modulate short and long-term memory?
Meneses, A. (2007) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2006.12.005 · Cited by 74
Parkinson's disease
Chase, T. N., Ng, L. K. Y., & Watanabe, A. M. (1972) · Neurology · doi:10.1212/wnl.22.5.479 · Cited by 69
Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity.
Hollister, A. S., Breese, G. R., & Mueller, R. A. (1979) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31520-x · Cited by 68
Serotonin receptors in brain revisited
Palacios, J. M. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.042 · Cited by 67
Levodopa Infusion Therapy in Parkinson Disease
Nyholm, D., & Aquilonius, S. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000144041.28224.b7 · Cited by 66
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats
Conti, M. M., Ostock, C. Y., Lindenbach, D., Goldenberg, A. A., Kampton, E. B., Dell'isola, R., Katzman, A. C., & Bishop, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.017 · Cited by 66
Ultrastructure of Secretory and High-Polymer Serum Immunoglobulin A of Human and Rabbit Origin
Svehag, S., & Bloth, B. (1970) · Science · doi:10.1126/science.168.3933.847 · Cited by 66
Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐ D ‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin
Morissette, M., Dridi, M., Calon, F., Tahar, A. H., Meltzer, L. T., Bédard, P. J., & Paolo, T. D. (2005) · Movement Disorders · doi:10.1002/mds.20654 · Cited by 65
Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate
Beaudoin‐Gobert, M., Epinat‐Duclos, J., Météreau, É., Duperrier, S., Neumane, S., Ballanger, B., Lavenne, F., Liger, F., Tourvielle, C., Bonnefoi, F., et al. (2015) · Brain · doi:10.1093/brain/awv183 · Cited by 65
Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia
Sellnow, R. C., Newman, J. H., Chambers, N., West, A. R., Steece‐Collier, K., Sandoval, I. M., Benskey, M. J., Bishop, C., & Manfredsson, F. P. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0653-7 · Cited by 64
Reuptake of l-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters
Kannari, K., Shen, H., Arai, A., Tomiyama, M., & Baba, M. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.03.059 · Cited by 62
Putaminal serotonergic innervation
Lee, J., Seo, S., Lee, J. S., Kim, H., Kim, Y. K., & Jeon, B. S. (2015) · Neurology · doi:10.1212/wnl.0000000000001909 · Cited by 59
Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia
Engeln, M., Deurwaerdère, P. D., Li, Q., Bézard, E., & Fernagut, P. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhu076 · Cited by 58
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats
Tronci, E., Napolitano, F., Muñoz, A., Fidalgo, C., Rossi, F., Björklund, A., Usiello, A., & Carta, M. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.07.017 · Cited by 57
5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model
Tronci, E., Lisci, C., Stancampiano, R., Fidalgo, C., Collu, M., Devoto, P., & Carta, M. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.08.014 · Cited by 55
Effects of L-Dopa on Efflux of Cerebral Monoamines from Synaptosomes
Ng, K. Y., Colburn, R. W., & Kopin, I. J. (1971) · Nature · doi:10.1038/230331a0 · Cited by 54
Morphological and electrophysiological properties of neurones in the dorsal vagal complex of the rat activated by arterial baroreceptors
Deuchars, J., Li, Y., Kasparov, S., & Paton, J. F. R. (2000) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(20000207)417:2 · Cited by 54
Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA–induced dyskinesia in rats
Ulusoy, A., Şahin, G., & Kirik, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003432107 · Cited by 53
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease
Fidalgo, C., Ko, W. K. D., Tronci, E., Li, Q., Stancampiano, R., Chuan, Q., Bézard, E., & Carta, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.04.027 · Cited by 50
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets
Jackson, M. J., Al‐Barghouthy, G., Pearce, R. K. B., Smith, L. A., Hagan, J. J., & Jenner, P. G. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.07.015 · Cited by 50
8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson??s disease
Mignon, L., & Wolf, W. A. (2005) · Neuroreport · doi:10.1097/00001756-200505120-00009 · Cited by 48
Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal 123I-FP-CIT SPECT study
Pasquini, J., Ceravolo, R., Brooks, D. J., Bonuccelli, U., & Pavese, N. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.03.025 · Cited by 47
The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.
Smith, R., Wu, K., Hart, T., Loane, C., Brooks, D., Björklund, A., Odin, P., Piccini, P., & Politis, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.037 · Cited by 43
The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque
Huot, P., Johnston, T. H., Fox, S. H., Newman‐Tancredi, A., & Brotchie, J. M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.033 · Cited by 42
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: Effect on adenosine A2Areceptors
Morissette, M., Dridi, M., Calon, F., Tahar, A. H., Meltzer, L. T., Bédard, P. J., & Paolo, T. D. (2006) · Synapse · doi:10.1002/syn.20295 · Cited by 41
Effects of acute tryptophan depletion on mood and suicidal ideation in bipolar patients symptomatically stable on lithium
Hughes, J. H., Dunne, F. J., & Young, A. H. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.5.447 · Cited by 41
The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective
Carta, M., & Björklund, A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1865-5 · Cited by 40
Efficacy and safety of 5‐hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding
Meloni, M., Puligheddu, M., Carta, M., Cannas, A., Figorilli, M., & Defazio, G. (2020) · European Journal of Neurology · doi:10.1111/ene.14179 · Cited by 40
Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease
Mazzucchi, S., Frosini, D., Ripoli, A., Nicoletti, V., Linsalata, G., Bonuccelli, U., & Ceravolo, R. (2014) · Acta Neurologica Scandinavica · doi:10.1111/ane.12314 · Cited by 38
Premotor Symptoms and Early Diagnosis of Parkinson's Disease
Adler, C. H. (2011) · International Journal of Neuroscience · doi:10.3109/00207454.2011.620192 · Cited by 34
Exogenousl-5-hydroxytryptophan is decarboxylated in neurons of the substantia nigra pars compacta and locus coeruleus of the rat
Arai, R., Karasawa, N., Nagatsu, T., & Nagatsu, I. (1995) · Brain Research · doi:10.1016/0006-8993(94)01259-k · Cited by 33
A Functional-Dimensional Approach to Depression: Serotonin Deficiency as a Target Syndrome in a Comparison of 5-Hydroxytryptophan and Fluvoxamine
Pöldinger, W., Calanchini, B., & Schwarz, W. (2010) · Psychopathology · doi:10.1159/000284698 · Cited by 32
Receptor subtype-specific modulation by dopamine of glutamatergic responses in striatal medium spiny neurons
Lin, J. Y., Dubey, R., Funk, G. D., & Lipski, J. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03757-5 · Cited by 30
Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats
Conti, M. M., Meadows, S. M., Melikhov-Sosin, M., Lindenbach, D., Hallmark, J., Werner, D. F., & Bishop, C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.025 · Cited by 29
Serotonin 5-HT1A Receptor Biased Agonists Display Differential Anxiolytic Activity in a Rat Social Interaction Model
Depoortère, R., Bardin, L., Varney, M. A., & Newman‐Tancredi, A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00661 · Cited by 26
Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding
Meloni, M., Puligheddu, M., Sanna, F., Cannas, A., Farris, R., Tronci, E., Figorilli, M., Defazio, G., & Carta, M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116869 · Cited by 26
Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode
Jangid, P., Malik, P., Singh, P., Sharma, M., & Gulia, A. (2012) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2012.05.011 · Cited by 25
Serotonin Neurons, Neuroplasticity, and Homeostasis of Neural Tissue
Azmitia, E. C. (1999) · Neuropsychopharmacology · doi:10.1038/sj.npp.1395346 · Cited by 24
Effect of selective and non-selective serotonin receptor activation on l-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats
Tronci, E., Fidalgo, C., Stancampiano, R., & Carta, M. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.06.034 · Cited by 21
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson’s disease?
Bézard, E., & Carta, M. (2015) · Brain · doi:10.1093/brain/awu407 · Cited by 18

Sorted by citations

Functional Neuroanatomy of the Basal GangliaPreprint
Lanciego, J. L., Luquin, N., & Obeso, J. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009621 · Cited by 848
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P., Feyder, M. T., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 492
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Calabresi, P., Filippo, M. D., Ghiglieri, V., Tambasco, N., & Picconi, B. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70218-0 · Cited by 398
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 333
Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA–Induced Dyskinesia and Histone Activation
Darmopil, S., Martín, A. B., Ruiz‐DeDiego, I., Ares‐Santos, S., & Moratalla, R. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.025 · Cited by 267

See all 131

Authors: CARTA, M., CARLSSON, T., MUNOZ, A., KIRIK, D., & BJORKLUND, A.
Affiliations: Lund University (SE)
Corresponding author: CARTA, M
ORCID: CARTA, M
CARLSSON, T
KIRIK, D
Venue: Progress in brain research
Publisher: Elsevier
Published: 2008
Volume: 172
Pages: 465-478
ISSN: 0079-6123 (ISSN-L)
DOI: 10.1016/s0079-6123(08)00922-9
OpenAlex: W1933235205
Cited by: 131
References: 157
Citations by year: 2026: 2 · 2025: 4 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 8 · 2019: 2 · 2018: 2 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 13 · 2013: 14 · 2012: 11
FWCI: 37.83
Type: book chapter
Language: en
Open access: closed
Locations: Progress in brain research (publishedVersion)
PubMed (publishedVersion)
UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
Lund University Publications (Lund University) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: serotonin, dopamine, levodopa-induced dyskinesia, Parkinson's disease, serotonergic system, serotonergic neurons, treatment options
MeSH terms: Animals, Clinical Trials as Topic, Dopamine, Dyskinesia, Drug-Induced, Humans, Levodopa, Parkinson Disease, Receptors, Dopamine, Receptors, Serotonin, Serotonin, Presynaptic Terminals, Protein Isoforms, Parkinsonian Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Serotonin–dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks